PDL BioPharma, Inc. (NASDAQ:PDLI)
A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Jordrok
(99.00)
Submitted: 5/13/2013 12:24:01 PM :
Start Price:
$7.99
PDLI Score:
+3.85
Mechanical investing
Recs
tgainesphd
(63.28)
Submitted: 4/18/2013 8:01:13 PM :
Start Price:
$7.49
PDLI Score:
+4.85
Good growth potential.
Recs
Aquinas31
(41.26)
Submitted: 4/3/2013 4:56:19 PM :
Start Price:
$7.33
PDLI Score:
+7.92
Dividends going up, probably hits 8+ by 4th quarter
Recs
dunloggin
(74.37)
Submitted: 2/5/2013 1:45:05 PM :
Start Price:
$6.65
PDLI Score:
+16.57
Dividend paying stock.
Recs
bIlluminati
(31.13)
Submitted: 1/23/2013 10:50:58 AM :
Start Price:
$6.76
PDLI Score:
-12.91
Patent usage running out. Six more quarters of earnings. Should be trading for cash plus 4-6x current quarter's earnings.
Recs
pavlos1971
(99.61)
Submitted: 1/2/2013 3:58:59 PM :
Start Price:
$5.94
PDLI Score:
-16.45
Short in RL@7.31
Recs
pdhaag
(75.40)
Submitted: 10/15/2012 9:18:41 PM :
Start Price:
$7.84
PDLI Score:
+7.33
Most of it's patents are set to expire between 2014 and 2017, at which point revenue will drop dramatically. It's only a matter of time.
Recs
EnigmaDude
(97.27)
Submitted: 10/8/2012 11:29:41 PM :
Start Price:
$7.75
PDLI Score:
-5.54
biotech trading for a P/E of 6 with a 7% dividend!
Recs
line70day
(25.31)
Submitted: 9/6/2012 8:11:36 AM :
Start Price:
$7.10
PDLI Score:
+1.36
Co.depends on royalities rights for many high profile drugs 3% royalty on sales out side the U.S. 15% growth on xalair & tysabri 13% sales growth each .Has protecion certificates in Europe & dividend of 8.2%
Recs
FoxForce5contest
(49.22)
Submitted: 8/18/2012 9:18:30 PM :
Start Price:
$6.94
PDLI Score:
+4.27
on 8-18-12 Momentum21 picked PDLI
Recs
myfairshare
(< 20)
Submitted: 8/17/2012 6:04:53 PM :
Start Price:
$6.94
PDLI Score:
+4.27
I think the royalties are the best position to be in, for the pharmaceutical plays.
Recs
SamsaricSufferer
(< 20)
Submitted: 7/4/2012 8:35:17 PM :
Start Price:
$6.35
PDLI Score:
+11.20
Biotech with solid pipeline
Recs
OklaBoston
(< 20)
Submitted: 5/16/2012 4:58:44 PM :
Start Price:
$5.84
PDLI Score:
+18.99
Shouldn't stay below $10 very long, could go over $15 if earnings live up to forecasts.
Recs
DaveKATL
(38.18)
Submitted: 5/4/2012 9:05:19 PM :
Start Price:
$5.79
PDLI Score:
+26.28
Strictly a momentum play. They have no drugs in the pipeline and it doesn't look like they're planning anymore - it's like their just burning this company bright and getting what they can out of it.
Recs
nveagle
(66.07)
Submitted: 1/18/2012 12:22:04 PM :
Start Price:
$5.64
PDLI Score:
+21.77
Potential in the long term.
Recs
jimscottage11
(< 20)
Submitted: 12/22/2011 10:01:43 AM :
Start Price:
$5.50
PDLI Score:
+19.85
High quarterly dividend.(10% yearly) Patents expire in 2015 though.
Recs
maniacdog
(< 20)
Submitted: 7/15/2011 3:57:40 PM :
Start Price:
$5.31
PDLI Score:
+31.52
I bought 550 shares in real life today I hope I am right.
Recs
eesirrius
(< 20)
Submitted: 7/15/2011 10:24:57 AM :
Start Price:
$5.33
PDLI Score:
+30.69
MFI Screen
Recs
CushCap
(23.09)
Submitted: 7/14/2011 10:09:03 AM :
Start Price:
$5.45
PDLI Score:
+28.81
Klarman doubled down earlier this year, and won right to pursue lawsuit in Nevada courts. Importantly, they didn't win the lawsuit yet, but the court deemed it valid: a small step in a process that could lead to tremendous upside. And in the event that this doesn't happen there appears to be enought value in their existing business (even though it is in terminal decline) to support their stock price. I am very early in my research, but this is my general understanding of the investment case so far.
Recs
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 129 : 1 2 3 4 5 6 7 Next »